176 related articles for article (PubMed ID: 16463547)
1. [Erlotinib. A new option for non-small cell lung cancer].
Polk B
Med Monatsschr Pharm; 2006 Jan; 29(1):4-6. PubMed ID: 16463547
[No Abstract] [Full Text] [Related]
2. Erlotinib and maintenance therapy of non-small cell lung cancer. Inadequate assessment; authorisation unjustified.
Prescrire Int; 2011 Oct; 20(120):234. PubMed ID: 21970082
[No Abstract] [Full Text] [Related]
3. Pulmonary fibrosis in a patient treated with erlotinib.
Bach JP; Kiessling AM; Kleinhans A; Faoro C; Gorg C; Riera-Knorrenschild J; Schwella N; Wagner HJ; Neubauer A
Onkologie; 2006 Jul; 29(7):342-3. PubMed ID: 16874020
[No Abstract] [Full Text] [Related]
4. Modern treatment of lung cancer: case 2. Response to erlotinib after failure of gefitinib in a patient with advanced non-small-cell lung carcinoma.
Garfield DH
J Clin Oncol; 2005 Oct; 23(30):7738-40. PubMed ID: 16234533
[No Abstract] [Full Text] [Related]
5. Gefitinib or erlotinib in the treatment of advanced non-small cell lung cancer.
Shao YY; Lin CC; Yang CH
Discov Med; 2010 Jun; 9(49):538-45. PubMed ID: 20587343
[TBL] [Abstract][Full Text] [Related]
6. APL during gefitinib treatment for non-small-cell lung cancer.
Uchida A; Matsuo K; Tanimoto M
N Engl J Med; 2005 Feb; 352(8):843. PubMed ID: 15728826
[No Abstract] [Full Text] [Related]
7. The rational basis of using novel targeted biological agents in non-small cell lung cancer.
Ciardiello F
Suppl Tumori; 2002; 1(4):S31-3. PubMed ID: 12415813
[No Abstract] [Full Text] [Related]
8. High exposure to erlotinib and severe drug-induced interstitial lung disease in patients with non-small-cell lung cancer.
Fujita K; Hirose T; Kusumoto S; Sugiyama T; Shirai T; Nakashima M; Akiyama Y; Sasaki Y
Lung Cancer; 2014 Oct; 86(1):113-4. PubMed ID: 25123334
[No Abstract] [Full Text] [Related]
9. Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.
Gao H; Ding X; Wei D; Cheng P; Su X; Liu H; Aziz F; Wang D; Zhang T
Anticancer Drugs; 2011 Oct; 22(9):842-52. PubMed ID: 21808188
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
Smith J
Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
[TBL] [Abstract][Full Text] [Related]
11. Safety profiles of erlotinib therapy in patients with advanced non-small-cell lung cancer.
Hotta K; Kiura K
Expert Rev Anticancer Ther; 2011 Jul; 11(7):991-7. PubMed ID: 21806322
[TBL] [Abstract][Full Text] [Related]
12. Erlotinib-induced acute interstitial lung disease associated with extreme elevation of the plasma concentration in an elderly non-small-cell lung cancer patient.
Tsubata Y; Hamada A; Sutani A; Isobe T
J Cancer Res Ther; 2012; 8(1):154-6. PubMed ID: 22531540
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial of Iressa.
FDA Consum; 2005; 39(2):4. PubMed ID: 16121415
[No Abstract] [Full Text] [Related]
14. Avastin-Tarceva combination fails in lung cancer.
Jones D
Nat Biotechnol; 2009 Feb; 27(2):108-9. PubMed ID: 19204674
[No Abstract] [Full Text] [Related]
15. Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int; 2010 Jun; 19(107):113. PubMed ID: 20738034
[No Abstract] [Full Text] [Related]
16. Side effects and good effects from new chemotherapeutic agents. Case 1. Gefitinib-induced interstitial fibrosis.
Nagaria NC; Cogswell J; Choe JK; Kasimis B
J Clin Oncol; 2005 Apr; 23(10):2423-4. PubMed ID: 15800334
[No Abstract] [Full Text] [Related]
17. Advances in the treatment of non-small cell lung cancer.
Saijo N
Cancer Treat Rev; 2008 Oct; 34(6):521-6. PubMed ID: 18501519
[TBL] [Abstract][Full Text] [Related]
18. Gefitinib does not increase survival in lung cancer patients.
Golsteyn RM
Drug Discov Today; 2005 Mar; 10(6):381. PubMed ID: 15808815
[No Abstract] [Full Text] [Related]
19. The current situation: erlotinib (Tarceva) and gefitinib (Iressa) in non-small cell lung cancer.
Comis RL
Oncologist; 2005 Aug; 10(7):467-70. PubMed ID: 16079313
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer.
Wang MZ; Li LY; Wang SL; Zhang XT; Zhong W; Zhang L
Chin Med J (Engl); 2006 Jan; 119(1):63-8. PubMed ID: 16454984
[No Abstract] [Full Text] [Related]
[Next] [New Search]
